Investegate announcements from Clinigen, Clinigen notes results from the MIROCALS trial investigating low dose Proleukin® (aldesleukin) in patients with amyotrophic lateral sclerosis
8 December 2022 Clinigen notes results from the MIROCALS trial investigating low dose Proleukin (aldesleukin) in patients with amyotrophic lateral sclerosis Clinigen Limited
/PRNewswire/ The "Kidney Cancer Drugs Global Market Report 2022, Type, Product, End Users" report has been added to ResearchAndMarkets.com s offering. The.